Synthesis and biological evaluation of heteroaryl styryl sulfone derivatives as anticancer agents
- 1 December 2016
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (23) , 5674-5678
Abstract
No abstract availableKeywords
Funding Information
- South Australia Cancer Council
- South Australia Health and Medical Institute
This publication has 18 references indexed in Scilit:
- Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid MalignanciesClinical Cancer Research, 2014
- Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.NaLeukemia Research, 2012
- Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure–Activity Relationship, and Biological ActivityJournal of Medicinal Chemistry, 2011
- Effect of ON 01910.Na, an Anticancer Mitotic Inhibitor, on Cell-Cycle Progression Correlates with RanGAP1 HyperphosphorylationCancer Research, 2011
- Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologyThe Oncologist, 2009
- Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid TumorsJournal of Clinical Oncology, 2008
- ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentCancer Cell, 2005
- Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and PhosphorylationJournal of Biological Chemistry, 2004
- Checkpoint Kinase 2 (Chk2) Monomers or Dimers Phosphorylate Cdc25C after DNA Damage Regardless of Threonine 68 PhosphorylationJournal of Biological Chemistry, 2002
- Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathwayOncogene, 1999